Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B

doi:10.3748/wjg.v8.i4.679

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 4

This Article

Citation of this article

Corresponding Author of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (5998)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-2) series, Tables (1-11) series.

Item

Count

PDF

456

HTML

5040

Figures (1-2)

241

Tables (1-11)

261

Sum=5998

Aug 15, 2002 (publication date) through Feb 21, 2025

Times Cited of This Article

Times Cited (97)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Viral Hepatitis

World J Gastroenterol. Aug 15, 2002; 8(4): 679-685
Published online Aug 15, 2002. doi: 10.3748/wjg.v8.i4.679

Table 1 Ultrasound image scoring for liver fibrosis

Items	1	2	3
Liver surface	Normal (smooth)	Irregular	Waved-shaped (or serrated)
Liver edge	Normal (sharp)	Blunt at tip	Blunt at the edge
Liver parenchyma	Normal (even)	Rough	Nodular (or patch-like)
Intra-hepatic vessels	Normal (clear)	Elusive	Unevenly narrow, wide, thick or thin

Table 2 Correlation between serum fibrotic markers and fibrotic stages

Stages (n)	HA (μg/L)	LM (μg/L)	IV-C (μg/L)	PIIIP (μg/L)
S0 (4)	103 ± 67.6	116 ± 34.8	232 ± 148	6.7 ± 2.3
S1 (14)	156 ± 175	103 ± 30	129 ± 92^a^c	7.4 ± 3.1^a^c
S2 (31)	197 ± 175	99 ± 26.5	178 ± 138	8.5 ± 4.1^a
S3 (35)	252 ± 243	107 ± 22	227 ± 123	10.8 ± 4.9
S4 (36)	239 ± 176	108 ± 22.6	232 ± 158	13 ± 7.8

^aP < 0.05, vs S4;

^cP < 0.05, S3.

Table 3 Correlation between serum fibrotic markers and inflammatory grades

Grades (n)	HA (μg/L)	LM (μg/L)	IV-C (μg/L)	PIIIP (μg/L)
G0 (1)	96	106	212	9.2
G1 (14)	136 ± 161^a^c	119 ± 26	146 ± 92^a	6.38 ± 2.4^a^c
G2 (35)	165 ± 158^a	96 ± 22	178 ± 128^a	7.71 ± 3.7^a^c
G3 (49)	258 ± 216	105 ± 25	211 ± 129	12 ± 5.85
G4 (21)	276 ± 202	107 ± 24	276 ± 178	14 ± 7.44

^aP < 0.05, vs S4;

^cP < 0.05, S3.

Table 4 Serum HA, LM, IV-C and PIIIP contents before, during and after treatment

		HA (μg/L)	LM (μg/L)	IV-C (μg/L)	PIIIP (μg/L)
IFN-γ group	Before	250 ± 210	94 ± 27	112 ± 64	10.4 ± 5.0
	During	225 ± 248	110 ± 22	219 ± 143	10.2 ± 4.4
	After	185 ± 172	104 ± 26	212 ± 105	8.0 ± 2.8
SA-B group	Before	267 ± 211	103 ± 17	294 ± 155	13.2 ± 8.1
	During	219 ± 243	117 ± 21	248 ± 164	11.9 ± 4.9
	After	169 ± 183^a	118 ± 24	190 ± 142^b^c	9.7 ± 5.3

^aP < 0.05,

^bP < 0.01, vs before treatment;

^cP < 0.05, vs during treatment.

Table 5 Abnormal rates of serum fibrotic markers before and after treatment (abnormal rate (%) = number of abnormal cases/total cases)

Groups		HA > 110 μg/L	LN > 132 μg/L	IV-C > 140 μg/L	PIIIP ≥ 5 μg/L
IFN-γ	Before	21/30 (70%)	1/30 (3.33%)	6/30 (20.0%)	20/29 (68.97%)
	After	17/30 (56.7%)	3/30 (10.0%)	20/30 (66.7%)	25/29 (86.2%)
SA-B	Before	24/30 (80%)	1/30 (3.33%)	24/30 (80.0%)	26/28 (92.86%)
	After	11/30 (36.67%)^a	7/30 (23.23%)	15/30 (50.0%)^a	25/28 (89.29%)

^aP < 0.05, vs before treatment.

Table 6 Decrease of 4 serum fibrotic markers > 30% after treatment in two groups

Groups	Total number 3	Decrease of markers > 30%	Decrease of 2 markers > 30%	Decrease of 1 marker > 30%
IFN-γ	30	1 (3.33%)	6 (20%)	13 (43.33%)
SA-B	30	9 (30%)	7 (23.33%)	7 (23.33%)

P < 0.05, vs IFN-γ

Table 7 Change of ALT activities before and after treatment n (%)

Group	Recovered	Decreased (> 50%)	Decreased (< 50%)	Stable	Increased
IFN-γ	6 (20)	4 (13.33)	4 (13.33)	2 (6.67)	14 (46.67)
SA-B	6 (20)	5 (16.67)	8 (26.67)	4 (13.33)	7 (23.33)^a

^aP < 0.05, vs IFN-γ.

Table 8 Change of AST activities before and after treatment n (%)

Group	Recovered	Decreased (> 50%)	Decreased (< 50%)	Stable	Increased
IFN-γ	8 (26.67)	3 (10.0)	4 (13.33)	4 (13.33)	11 (36.67)
SA-B	7 (23.33)	2 (6.67)	4 (13.33)	5 (16.67)	12 (40.00)

Table 9 Change of ultrasound image scoring

Group	n	Before treatment	After treatment	Improved n (%)	Deteriorated n (%)
IFN-γ	29	5.38 ± 1.52	5.75 ± 1.45	4 (13.79)	11 (37.93)
SA-B	30	5.10 ± 1.52	4.70 ± 1.44	9 (30)	2 (6.67)^a

Comparison of χ² test between two groups,

^aP < 0.05

Table 10 Correlation between change of fibrotic stages before and after treatment, liver function and serum fibrotic markers before treatment in SA-B group

Items	*Improved (n =* 11)**	Unchanged (n = 13)	Deteriorated (n = 6)
Albumin (g/L)	40 ± 4.4	39.3 ± 6.5	39.5 ± 3.0
Globulin (g/L)	31.1 ± 6.7	33.9 ± 6.9	30.9 ± 8.5
ALT (U)	64 ± 41^a	108 ± 83	201 ± 155
AST (U)	48 ± 29^b	73 ± 55^a	155 ± 108
GGT (U)	72 ± 44	99 ± 47	96 ± 54
Total bilirubin (mmol)	14.9 ± 3.9^b	15.0 ± 6.6^a	21 ± 10
Direct bilirubin (mmol)	2.9 ± 1.7	3.1 ± 2.3	5.0 ± 4.0
HA (μg/L)	172 ± 110	292 ± 188	386 ± 330
LN (μg/L)	106 ± 10	107 ± 21	91 ± 18
IV-C (μg/L)	248 ± 88	352 ± 176	284 ± 164
PIIIP (μg/L)	10.2 ± 6.8	14.8 ± 7.3	15 ± 10.2

Compared with elevation of stages,

^aP < 0.05,

^bP < 0.01

Table 11 Correlation between change of fibrotic stages before and after treatment, liver function and serum fibrotic markers before treatment in IFN-γ group

Items	Improved (n = 9)	Unchanged (n = 12)	Deteriorated (n = 9)
Albumin (g/L)	39.9 ± 5.0	40.8 ± 4.6	40.6 ± 6.7
Globulin (g/L)	28.1 ± 4.6	30.7 ± 4.0	31.9 ± 5.3
ALT activities (U)	94 ± 56	79 ± 51	171 ± 286
AST activities (U)	77 ± 53	56 ± 33	80 ± 73
GGT activities (U)	76 ± 41	76 ± 48	81 ± 40
Total bilirubin (mmol)	13.4 ± 7.6	16.5 ± 6.4	18.9 ± 7.0
Direct bilirubin (mmol)	3.0 ± 2.2	3.6 ± 2.5	3.3 ± 2.0
HA (μg/L)	219 ± 230	284 ± 246	237 ± 145
LM (μg/L)	97 ± 34	87 ± 18	102 ± 30
IV-C (μg/L)	128 ± 84	104 ± 56	92 ± 32
PIIIP (μg/L)	12.0 ± 6.2	9.1 ± 5.5	10.9 ± 2.3

Citation: Liu P, Hu YY, Liu C, Zhu DY, Xue HM, Xu ZQ, Xu LM, Liu CH, Gu HT, Zhang ZQ. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol 2002; 8(4): 679-685
URL: https://www.wjgnet.com/1007-9327/full/v8/i4/679.htm
DOI: https://dx.doi.org/10.3748/wjg.v8.i4.679